Biomarker-driven diagnosis of diffuse gliomas.
暂无分享,去创建一个
[1] R. McLendon,et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma , 2006, Molecular Cancer Therapeutics.
[2] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[3] Y. Yonekawa,et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] S. Pfister,et al. Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy , 2014, Clinical Cancer Research.
[5] Martin Sill,et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma , 2014, Acta Neuropathologica.
[6] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[7] Jianping Ding,et al. Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity* , 2004, Journal of Biological Chemistry.
[8] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[9] Sabine Mueller,et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.
[10] A. Iafrate,et al. Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas , 2014, Clinical Cancer Research.
[11] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[12] Arie Perry,et al. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.
[13] Candace Chisolm,et al. Glioblastoma with Oligodendroglioma Component (GBM‐O): Molecular Genetic and Clinical Characteristics , 2013, Brain pathology.
[14] K. Aldape,et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.
[15] Pieter Wesseling,et al. International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.
[16] J. Cairncross,et al. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. , 1994, Journal of the National Cancer Institute.
[17] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[18] B. Garcia,et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.
[19] N. Probst-Hensch,et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.
[20] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[21] Daniel J Brat,et al. Molecular genetics of gliomas. , 2014, Cancer journal.
[22] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[23] R. McLendon,et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.
[24] C. Hartmann,et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas , 2012, Acta Neuropathologica.
[25] Y. Katayama,et al. Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas , 2003, Brain pathology.
[26] H. Zentgraf,et al. Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.
[27] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[28] Andrey Korshunov,et al. Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.
[29] Arie Perry,et al. Practical Surgical Neuropathology: A Diagnostic Approach , 2010 .
[30] E. Shaw,et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.
[31] BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications , 2011, PloS one.
[32] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[33] R. Mirimanoff,et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial , 2012, Acta Neuropathologica.
[34] P. Kleihues,et al. Genetic profile of astrocytic and oligodendroglial gliomas , 2011, Brain Tumor Pathology.
[35] S. Al-Sarraj,et al. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. , 2013, Neuro-oncology.
[36] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[37] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[38] Wei Wu,et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers , 2012, The Journal of pathology.
[39] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[40] R. McLendon,et al. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. , 2015, Archives of Pathology & Laboratory Medicine.
[41] D. Brat,et al. Diagnosis of malignant glioma: role of neuropathology , 2008, Journal of Neuro-Oncology.
[42] R. McLendon,et al. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. , 1999, Neuro-oncology.
[43] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[44] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[45] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.
[46] D. Brat,et al. PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma , 2013, Brain pathology.
[47] David T. W. Jones,et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma , 2014, Acta Neuropathologica.
[48] P. Burger,et al. Clinicopathologic Features of Pediatric Oligodendrogliomas: A Series of 50 Patients , 2014, The American journal of surgical pathology.
[49] B. O'neill,et al. MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[50] Akira Matsumura,et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing , 2011, Brain Tumor Pathology.
[51] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[52] H. Heinzl,et al. Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.
[53] F. Rodriguez,et al. Pathological and molecular advances in pediatric low-grade astrocytoma. , 2013, Annual review of pathology.
[54] J. Herman,et al. CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[55] R. McLendon,et al. Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.
[56] P. Cassoni,et al. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors , 2012, Journal of Neuro-Oncology.
[57] G. Fuller,et al. Moving toward molecular classification of diffuse gliomas in adults , 2012, Neurology.
[58] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[59] J. Herman,et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.
[60] P. Kleihues,et al. The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.
[61] P. Cassoni,et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors , 2011, Journal of Neuro-Oncology.
[62] David T. W. Jones,et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge , 2014, Nature Reviews Cancer.
[63] P. Bailey,et al. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis , 1970 .
[64] Y. Yonekawa,et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. , 2001, Carcinogenesis.
[65] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[66] Caroline Dehais,et al. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. , 2014, Neuro-oncology.
[67] R. Beroukhim,et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas , 2014, Oncotarget.
[68] D. Schiff,et al. Update on molecular findings, management and outcome in low-grade gliomas , 2010, Nature Reviews Neurology.
[69] Alexander R. Pico,et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.
[70] B. Scheithauer,et al. Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading , 2001, Journal of neuropathology and experimental neurology.
[71] Y. Suh,et al. IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA‐Mediated Clamping PCR , 2013, Brain pathology.
[72] D. Brat,et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group , 2010, Child's Nervous System.
[73] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[74] I. Ferrer,et al. Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas , 2005, Clinical Cancer Research.
[75] A. von Deimling,et al. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. , 2012, International journal of oncology.
[76] David T. W. Jones,et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.
[77] Hendrik Witt,et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma , 2009, Acta Neuropathologica.
[78] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[79] J. Biegel,et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.
[80] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[81] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[82] Andrey Korshunov,et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.
[83] David T. W. Jones,et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma , 2014, Acta Neuropathologica.
[84] D K Pearl,et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.
[85] Yuchen Jiao,et al. Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011, Science.
[86] S. Al-Sarraj,et al. Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma , 2013, PloS one.
[87] N. Stanietsky,et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.
[88] O. Chinot,et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis , 2010, Acta Neuropathologica.